SCHEMBL8619265

SCHEMBL8619265

Cc1ccc2c(C(=O)O)cc(-c3ccccc3)nc2c1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.81
ALDH1A1 P00352 2/20 0.81
HSD17B10 Q99714 2/20 0.81
PDE10A Q9Y233 2/20 0.72
LMNA P02545 1/20 0.72
SMN1; SMN2 Q16637 1/20 0.72
DHODH Q02127 5/20 0.68
TP53 P04637 1/20 0.63
CYP1A2 P05177 1/20 0.63
CYP2C19 P33261 1/20 0.63
HIF1A Q16665 1/20 0.63
POLB P06746 1/20 0.61
MAPK1 P28482 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
CYP3A4 P08684 1/20 0.59
AKR1C3 P42330 1/20 0.58
AKR1C2 P52895 1/20 0.58
AKR1C1 Q04828 1/20 0.58
PPARA Q07869 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1898810 0.90 KDM4E (1.00) KDM4EALDH1A1HSD17B10PDE10ALMNA
SCHEMBL19475461 0.87 KDM4E (0.70) KDM4EALDH1A1HSD17B10PDE10ALMNA
SCHEMBL4017739 0.87 DHODH (0.80) KDM4EALDH1A1HSD17B10PDE10ALMNA
SCHEMBL29788466 0.87 DHODH (0.80) KDM4EALDH1A1HSD17B10PDE10ALMNA
SCHEMBL19508615 0.86 PLA2G2A (0.65) KDM4EALDH1A1HSD17B10PDE10ALMNA
Cinchophen SCHEMBL29376617 0.84 KDM4E (1.00) KDM4EALDH1A1HSD17B10PDE10ALMNA
Cinchophen SCHEMBL7588217 0.84 KDM4E (1.00) KDM4EALDH1A1HSD17B10PDE10ALMNA
Cinchophen SCHEMBL25519 0.84 KDM4E (1.00) KDM4EALDH1A1HSD17B10PDE10ALMNA
SCHEMBL8614836 0.84 KDM4E (0.75) KDM4EALDH1A1HSD17B10PDE10ALMNA
SCHEMBL6335134 0.84 POLB (0.76) KDM4EALDH1A1HSD17B10PDE10ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220169640-A1 PRODUCTION METHOD OF QUINOLINECARBOXAMIDE DERIVATIVE OR PRODUCTION INTERMEDIATE THEREOF KABUSHIKI KAISHA YAKULT HONSHA (JP) 2022-06-02 US disclosed
EP-3943159-A1 PRODUCTION METHOD OF QUINOLINECARBOXAMIDE DERIVATIVE OR PRODUCTION INTERMEDIATE THEREOF Kabushiki Kaisha Yakult Honsha (JP) 2022-01-26 EP disclosed
WO-2020196327-A1 PRODUCTION METHOD OF QUINOLINECARBOXAMIDE DERIVATIVE OR PRODUCTION INTERMEDIATE THEREOF 株式会社ヤクルト本社 2020-10-01 WO disclosed
EP-0726254-B1 Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds MITSUI TOATSU CHEMICALS (JP) 1998-05-06 EP disclosed
US-5627193-A MEDICAL DIAGNOSIS, CARDIOVASCULAR DIAORDERS AND PROTECTION OF ORGANS FOR TRANSPLANTATION MITSUI TOATSU CHEMICALS, INC. (JP) 1997-05-06 US disclosed
EP-0726254-A1 Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds MITSUI TOATSU CHEMICALS, Inc. (JP) 1996-08-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169640-A1 PRODUCTION METHOD OF QUINOLINECARBOXAMIDE DERIVATIVE OR PRODUCTION INTERMEDIATE THEREOF BCKDK, CBR3, NQO2 KDM4E 363/4885ALDH1A1 213/4885HSD17B10 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.